Dr. Pulsipher on MRD in Pediatric Patients Treated With CAR T Cells

Michael Pulsipher, MD
Published: Thursday, Dec 06, 2018



Michael Pulsipher, MD, section head, Blood and Marrow Transplantation, Children's Hospital Los Angeles, professor of pediatrics, USC Keck School of Medicine, discusses the role of minimal residual disease (MRD) testing in pediatric patients treated with chimeric antigen receptor (CAR) T-cell therapy.

In pediatric patients with relapsed/refractory acute lymphoblastic leukemia, treatment with the CD-19 targeted CAR T-cell therapy tisagenlecleucel (Kymriah) demonstrated sustained rates of relapse-free survival and overall survival at 24 months, according to updated data presented at the 2018 ASH Annual Meeting. Based on an exploratory analysis from this study, Pulsipher adds, researchers might have an earlier idea of which patients will derive the most benefit from CAR T cells.

MRD testing was performed after the 28-day cycle of CAR T-cell therapy. Results showed that patients who demonstrated what was defined as an MRD-negative remission had a progression-free survival (PFS) rate of 80% that stretched into the 2-year follow-up range. On the other hand, Pulsipher says, patients who demonstrated MRD positivity had a 2-year PFS rate of 30%.
SELECTED
LANGUAGE


Michael Pulsipher, MD, section head, Blood and Marrow Transplantation, Children's Hospital Los Angeles, professor of pediatrics, USC Keck School of Medicine, discusses the role of minimal residual disease (MRD) testing in pediatric patients treated with chimeric antigen receptor (CAR) T-cell therapy.

In pediatric patients with relapsed/refractory acute lymphoblastic leukemia, treatment with the CD-19 targeted CAR T-cell therapy tisagenlecleucel (Kymriah) demonstrated sustained rates of relapse-free survival and overall survival at 24 months, according to updated data presented at the 2018 ASH Annual Meeting. Based on an exploratory analysis from this study, Pulsipher adds, researchers might have an earlier idea of which patients will derive the most benefit from CAR T cells.

MRD testing was performed after the 28-day cycle of CAR T-cell therapy. Results showed that patients who demonstrated what was defined as an MRD-negative remission had a progression-free survival (PFS) rate of 80% that stretched into the 2-year follow-up range. On the other hand, Pulsipher says, patients who demonstrated MRD positivity had a 2-year PFS rate of 30%.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x